NOVOGENE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.81 CNY | -1.31% |
|
-3.47% | -45.12% |
| Apr. 12 | Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 27 | Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 2.33B 322M | Sales 2025 * | 2.78B 384M | Capitalization | 5.29B 731M |
|---|---|---|---|---|---|
| Net income 2024 * | 213M 29.42M | Net income 2025 * | 261M 36.05M | EV / Sales 2024 * | 2.27 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.9 x |
| P/E ratio 2024 * |
25.1
x | P/E ratio 2025 * |
20.4
x | Employees | 2,144 |
| Yield 2024 * |
0.78% | Yield 2025 * |
1.41% | Free-Float | 23.45% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.31% | ||
| 1 week | -3.47% | ||
| Current month | -9.41% | ||
| 1 month | -18.92% | ||
| 3 months | -32.26% | ||
| 6 months | -40.72% | ||
| Current year | -45.12% |
1 week
12.50
13.41
1 month
12.5016.75
Current year
12.1723.56
1 year
12.1739.78
3 years
12.1769.82
5 years
12.1769.82
10 years
12.1769.82
| Managers | Title | Age | Since |
|---|---|---|---|
Rui Qiang Li
CEO | Chief Executive Officer | 44 | 11-03-14 |
Shi Shan Shi
DFI | Director of Finance/CFO | 42 | 14-03-31 |
Qi Feng Wang
BRD | Director/Board Member | 46 | 12-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rui Qiang Li
CEO | Chief Executive Officer | 44 | 11-03-14 |
Qi Feng Wang
BRD | Director/Board Member | 46 | 12-01-31 |
Chun Fei Wang
BRD | Director/Board Member | 44 | 22-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 12.81 | -1.31% | 1,809,491 |
| 24-04-18 | 12.98 | -0.99% | 2,180,109 |
| 24-04-17 | 13.11 | +2.58% | 2,778,724 |
| 24-04-16 | 12.78 | -4.27% | 4,792,227 |
| 24-04-15 | 13.35 | +0.60% | 5,098,403 |
End-of-day quote Shanghai S.E., April 18, 2024
More quotes
Novogene Co Ltd is a China-based company principally engaged in gene sequencing. The Company mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. Based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The Company's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The Company conducts its businesses in domestic and overseas markets.
Calendar
2024-04-23
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.81
CNY
Average target price
21.48
CNY
Spread / Average Target
+67.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -45.12% | 741M | |
| -18.11% | 8.02B | |
| +33.79% | 3.51B | |
| -29.02% | 2.97B | |
| -7.71% | 2.48B | |
| -14.30% | 2.23B | |
| -16.38% | 1.76B | |
| -22.17% | 1.44B | |
| -39.69% | 1.25B | |
| -11.20% | 1.11B |
- Stock Market
- Equities
- 688315 Stock
